{"denoms":[{"counts":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"62"},{"groupId":"BG005","value":"69"},{"groupId":"BG006","value":"18"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"267"}],"units":"Participants"}],"groups":[{"description":"Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG000","title":"Rhabdoid Tumors: Cohort 1"},{"description":"Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG001","title":"Synovial Sarcoma: Cohort 2"},{"description":"Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG002","title":"Other INI1-negative: Cohort 3"},{"description":"Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG003","title":"RMC: Cohort 4"},{"description":"Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG004","title":"ES: Cohort 5"},{"description":"Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG005","title":"ES Paired Biopsy: Cohort 6"},{"description":"Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG006","title":"Chordoma: Cohort 7"},{"description":"Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"BG007","title":"ES 1600 mg: Cohort 8"},{"description":"Total of all reporting groups","id":"BG008","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.31","value":"37.9"},{"groupId":"BG001","spread":"9.54","value":"38.8"},{"groupId":"BG002","spread":"16.94","value":"46.9"},{"groupId":"BG003","spread":"10.71","value":"30.7"},{"groupId":"BG004","spread":"15.08","value":"37.0"},{"groupId":"BG005","spread":"14.00","value":"41.3"},{"groupId":"BG006","spread":"17.49","value":"38.9"},{"groupId":"BG007","spread":"15.74","value":"40.9"},{"groupId":"BG008","spread":"14.89","value":"39.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"113"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"39"},{"groupId":"BG005","value":"43"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"154"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"21"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"53"},{"groupId":"BG005","value":"55"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"231"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"22"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"26"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"54"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"200"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"17"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) population included all participants who received at least 1 dose of tazemetostat."}